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Joint destruction in arthritis is often associated with high levels of inflammatory cytokines. Previous work has shown that inflammatory
conditions can alter the activities of glycosyltransferases that synthesize the glycan chains of glycoproteins, and that these changes in turn can
influence the functions of glycoproteins. We therefore examined glycosyltransferases involved in glycoprotein biosynthesis in primary cultures of
bovine articular chondrocytes and human chondrocytes isolated from knee cartilage of osteoarthritis patients. Bovine chondrocytes exhibited
enzyme activities involved in the synthesis of bi-antennary complex Asn-linked N-glycans, as well as the enzymes involved in the synthesis of
GalNAc-Ser/Thr-linked O-glycans with the core 1 structure. Human chondrocytes, in addition, were able to synthesize more complex O-glycans
with core 2 structures. TNFα was found to induce apoptosis in chondrocytes, and this process was associated with significant changes in lectin
binding to chondrocyte cell surface glycans. TGFβ increased cell proliferation, and had significant effects on cell surface glycosylation in bovine
but not in human cells. These cytokine-specific effects were partially correlated with changes in glycosyltransferase activities. Thus, chondrocytes
have many of the enzymes necessary for the synthesis of N- and O-glycan chains of glycoproteins. The O-glycosylation pathways and the effects
of TNFα and TGFβ on glycosylation differed between bovine and human chondrocytes. These alterations are of potential importance for the
regulation of the functions of cell surface receptors on chondrocytes, and for an understanding of the pathophysiology of arthritis.
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Chondrocytes are the main cell type found in cartilage that
produce glycoproteins and proteoglycans involved in main-
taining the extensive cartilage specific extracellular matrix
(ECM) along with its resilient and flexible properties. The
pathophysiology and joint destruction in osteoarthritis (OA)
and rheumatoid arthritis (RA) are associated with a high
degree of chondrocyte apoptosis and breakdown of cartilage
[1–4]. In mature cartilage, the differentiation of articular
chondrocytes is arrested before terminal differentiation and
these cells do not regenerate [5]. After joint injury or loss of⁎ Corresponding author. Department of Medicine, Division of Rheumatology,
Human Mobility Research Centre, Queen’s University, Etherington Hall,
Kingston, ON, Canada K7L 3N6. Tel.: +1 613 533 2927; fax: +1 613 549 2529.
E-mail address: brockhau@post.queensu.ca (I. Brockhausen).
0167-4889/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2006.09.022extracellular matrix (ECM) in OA, cells appear to become
more susceptible to apoptosis [6]. Apoptosis results in the
production of apoptotic bodies that are normally removed by
phagocytic cells, thus preventing the induction of an
inflammatory response [7]. However, articular cartilage is
not vascularized and therefore does not contain mononuclear
phagocytes for the clearance of apoptotic bodies. In addition,
there is little or no chondrocyte cell division in healthy
cartilage. Thus, chondrocyte apoptosis represents a serious
problem, leading to loss of cartilage.
Both OA and RA are associated with an up-regulation of
cytokines and growth factors [8]. These include the pro-
inflammatory cytokine tumor necrosis factor α (TNFα), as
well as the anti-inflammatory cytokine transforming growth
factor β (TGFβ). Both of these cytokines can alter cellular
glycosylation as well as the expression of specific glycopro-
teins and glycosyltransferases [9–17]. The resulting changes
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affect cell surface functions such as cell adhesion, cell surface
receptor activities and the induction of apoptosis. TGFβ
promotes cartilage homeostasis; it counterbalances the effects
of IL-1 in suppressing cartilage proteoglycan and collagen
synthesis, and may thus help chondrocytes to restore the ECM
in osteoarticular diseases [18,19]. Several members of the
TGFβ superfamily play important roles in cartilage and bone
growth, including the bone morphogenetic proteins (BMPs)
[20]. This is also demonstrated in mice harbouring mutations
in members of the TGFβ superfamily that display multiple
skeletal defects [21].
Numerous studies have shown a link between glycosylation
and cellular growth, differentiation and apoptosis [22–26]. The
apoptotic cytokine TNFα has been shown to alter the gene
expression and activities of specific glycosyltransferases in a
cell type-dependent manner [17,27]. TGFβ-1 induces cell
proliferation and appears to increase the overall N-glycosylation
of fibronectin produced by bovine chondrocytes [28]. Galectins
are Gal-binding lectins and are involved in the regulation of
growth and cell death. Galectin-3 is an anti-apoptotic lectin, and
has been shown to bind to Gal residues of glycoproteins on
chondrocyte cell surfaces and in the extracellular matrix. The
level of galectin-3 expression is increased in OA chondrocytes
[29]. Thus, galectin-3, and Gal-containing glycoconjugates on
chondrocyte cell surfaces regulate chondrocyte survival.
Although chondrocytes are known to synthesize numerous
glycoproteins involved in chondrocyte biology and cartilage
physiology, very little is known about the structures, biosynth-Fig. 1. Proposed O-glycosylation pathways in human and bovine chondrocytes.
The main paths in the biosynthesis of O-glycans, that have been studied in this
work, are shown. Based on glycosyltransferase activities, BC are expected to
have simple mucin type core 1-based O-glycans, similar to those in bovine
synoviocytes [52]. The pathways of O-glycosylation in HC are similar to those
of porcine endothelial cells [10]. HC are expected to have complex branched
core 2-based O-glycans. Path a, polypeptide GalNAc-transferase; path b, core 1
β3-Gal-transferase; path c, core 2 β6-GlcNAc-transferase; path d, β4-Gal-
transferase; path e, core 1 3-O-sulfotransferase (blocked arrow indicates lack of
activity); path f, core 1 α3-sialyltransferase. The activities of polypeptide
GalNAc-transferase (path a) and β4-Gal-transferase activity (path d) are greatly
increased by TNFα treatment of BC.esis and roles of glycoprotein-bound glycans [30–34]. In the
present study, we examined the biosynthetic pathways of
glycoproteins in cultured bovine chondrocytes (BC) and human
chondrocytes (HC) from osteoarthritis patients (Fig. 1) and
determined the activities of glycosyltransferases present in BC
and HC homogenates. In addition, we used lectins to determine
the relative amounts of specific cell surface glycans. We also
examined the metabolic effects of TNFα and TGFβ with
respect to the biosynthesis of glycoproteins and the cell surface
glycosylation phenotype. Specific glycosylation changes were
thus related to apoptosis and cell proliferation. This work is the
basis for further detailed studies on the mechanisms of action of
inflammatory cytokines in cartilage and contribute to our
understanding of cartilage homeostasis and pathophysiology.
2. Materials and methods
2.1. Reagents
Chemicals were obtained from Sigma (St. Louis, MO) unless otherwise
indicated. Culture media and fetal bovine serum (FBS) were purchased from
GIBCO BRL (Grand Island, NY). Glycosyltransferase substrates and standards
for high pressure liquid chromatography (HPLC) were obtained as described
[11,17,35]. Biotin-linked MAA lectin was purchased from Vector Laboratories
(Burlingame, CA); all other biotin-linked lectins were purchased from Sigma.
2.2. Cell cultures
Primary cultures of chondrocytes were obtained and maintained as previously
described [36]. Bovine articular cartilage was obtained from the ankles of 2 year old
cows at the abattoir. Tissuepieceswere digested at 37 °Covernightwith 160Units/ml
sterile collagenase IV (Sigma) in 10 ml DMEM-F12 medium containing 100 U/ml
penicillin and 100μg/ml Streptomycin and 20%FBS.Chondrocyteswere plated at a
cell density of one million cells per 75 cm2 plate in the same medium which was
gradually changed to 10% FBS. All in vitro experiments were carried out using
primary chondrocyte cultures between passage numbers 0 and 3. Collagen I and II
expression was analyzed byWestern blots using goat polyclonal IgG anti-collagen I
(C-18) and anti-collagen II (C-19), with secondary antibody bovine anti-goat IgG-
HRP (Santa Cruz Biotechnology). HRP activity was detected using ECLWestern
blotting luminal reagent (Santa Cruz Biotechnology).
HC were isolated similarly to the procedure used for BC. The original tissues
were frommale and female osteoarthritis patients undergoing surgery for knee or
hip replacement. The ages of patients varied between 65 and 75 years. Although
patients had osteoarthritis, the chosen tissues showed no visible pathology.
2.3. Cytokine treatments
Before cytokine treatments, cells were grown in medium containing a
reduced concentration of FBS (2%) for 48 h. Cells were then treated for 48 h
with medium containing 40 ng/ml human TNFα (R&D Systems, Minneapolis,
MN), or 0.0004% BSA for control cells. Alternatively, cells were treated with
5 to 10 ng/ml TGFβ (R&D Systems) for 48 h, or with 20 μM HCl and
0.001% BSA for control cells. Experiments in which TNFα or TGFβ effects
were compared were performed using the same batch of cells from the same
donor.
2.4. Apoptosis assays
Chondrocyte apoptosis was determined in cultures at 90% confluency. The
Annexin-biotin V staining kit (Annexin V-biotin apoptosis detection kit from
Oncogene) was used as well as the TdT-FragEL DNA fragmentation kit
(TUNEL; terminal deoxynucleotidyl transferase dUTP nicked end labeling from
Oncogene) by fluorescence microscopy as described [17] and by flow cytometry
(Beckman Coulter EPICS XL flow cytometer).
Table 1
Lectins used to detect carbohydrates on chondrocyte cell surfaces
Lectin Carbohydrate Specificity
WGA GlcNAc/sialic acid
PNA Galβ1-3GalNAc-
SNA Sialic acidα2-6Gal (NAc)-
MAA Sialic acidα2-3Gal-
ConA N-glycan cores
HP GalNAc-
Table 2
Comparison of glycosyltransferase activities in primary bovine and human
chondrocytes
Enzyme Substrate Activities (nmol/
h/mg)
BC HC
O-glycosylation pathway
Polypeptide
GalNAc-T
1 mM Acetyl-BpaPTPPP-NH2 2.6 27.7
Core 1 β3-Gal-T 2 mM GalNAcα-Bn 1.5 7.9
Core 2 β6-GlcNAc-T 2 mM Galβ3GalNAcα-Bn 0 1.3
Core 1 α3-sialyl-T 2 mM Galβ3GalNAcα-Bn 0.4 nd
Core 1 3-O-sulfo-T 2 mM Galβ3GalNAcα-Bn <0.001 <0.001
N-glycosylation pathway
GlcNAc-T I 1 mM Manα6(Manα3)Manβ-octyl 3.4 0.8
GlcNAc-T II 1 mM 6-deoxy-Manα6
(GlcNAcβ2Manα3) Manβ-octyl
2.6 1.8
GlcNAc-T III-V 1 mM GlcNAcβ2Manα6
(GlcNAcβ2Manα3) Manβ-octyl
<0.1 <0.1
GlcNAc-T V 2 mM GlcNAcβ2Manα6Glcβ-pnp <0.1 nd
N- and O-glycosylation pathway
β4-Gal-T 2 mM GlcNAcβ-Bn 10.4 6.7
Enzyme assays were carried out in at least duplicate determinations using
chondrocyte homogenates as described in Materials and methods. Values
obtained from duplicates varied by <15%. HC samples were obtained from OA
patients that had undergone surgery for knee replacement. The enzymes of the N-
andO-glycosylation pathwayswere studied using different cell preparations. BC,
bovine articular chondrocytes; Bn, benzyl; Bpa, 4-benzoyl-L-phenylalanine; HC,
human chondrocytes; nd, not determined; pnp, p-nitrophenyl; -T, transferase.
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For the determination of cell surface glycans by ELLA, cells were grown
on 96well plates. To prevent changes in cell numbers after cytokine treatment,
cells were grown to complete confluency. Monolayers were treated with
biotin-linked lectins (Table 1), followed by streptavidin-alkaline phosphatase
conjugate and measurements of alkaline phosphatase activity [17]. Controls
lacked the lectins. Enzyme reactions were carried out with p-nitrophenyl
phosphate substrate, and plates were read at 405 nm. Statistical analysis was
carried out with the t-test.
2.6. Proliferation assays
Cell numbers were determined by cell counting using a haemocytometer,
and by cell proliferation assays using [3H]thymidine incorporation. Cells were
seeded in 96 well plates at a density of 2500 cells/well and were used after
growth in 48 h to 40–50% confluency. [3H]thymidine was added to each well to
a final concentration of 1 μCi/ml and cells were incubated for 24 h. Cells were
then fixed with methanol/acetic acid (3/1), washed, and lysed in 1 N NaOH. The
radioactivity in cell lysates as a measure of cell proliferation was determined by
scintillation counting.
2.7. Transferase assays
For enzyme assays, cells released from culture plates with Trypsin/EDTA
were washed three times with PBS, and hand homogenized in 10 volumes of
0.25 M sucrose. Homogenates were stored at −80 °C. Glycosyltransferase
activities were assayed by HPLC, and sulfotransferase activities were assayed by
high voltage electrophoresis in Na-tetraborate, as described in detail [11,17,37].
Transferase assays have been performed in at least duplicate determinations,
with results varying by less than 15%.
Briefly, polypeptide GalNAc-transferase was assayed in a total volume of
40 μl, containing 1 mM acceptor substrate as indicated in Table 2, 0.84 mM
UDP-[3H]GalNAc donor substrate (2000 cpm/nmol), 12.5 mMMnCl2, 0.125 M
MES, pH 7, 0.125% Triton X-100, 10 mMAMP and 20 μl cell homogenate (3 to
16 μg protein). After incubation for 1 h at 37 °C, product was isolated by
chromatography using AG1x8, followed by HPLC using a C18 column and
acetonitrile/water mixture (22/78) as the mobile phase. The UVabsorbance and
radioactivity of fractions were recorded and product was quantified by
scintillation counting.
Core 1 β3-Gal-transferase was assayed similarly, using 2 mM acceptor
substrate, 1.2 mM UDP-[3H]Gal as the donor substrate (2000–4000 cpm/nmol),
as well as 5 mM γ-galactonolactone in the assay. The HPLC separation of
product was achieved with acetonitrile/water (10/90). Other Gal-transferases
were assayed under the same conditions as core 1 β3-Gal-transferase, but using
2 mM GlcNAcβ-Bn acceptor substrate and 0.9 mM UDP-[3H]Gal.
Core 2 β6-GlcNAc-transferase assays contained 2 mM acceptor substrate,
0.85 to 1 mM UDP-[3H]GlcNAc donor substrate (3100–3600 cpm/nmol),
0.125 M MES, pH 7, 0.125% Triton X-100, 10 mM AMP, 5 mM γ-
galactonolactone, 0.125 M GlcNAc, and 20 μl cell homogenate (3 to 16 μg
protein). Product was separated on HPLC using acetonitrile/water (6/94).
GlcNAc-transferase I, II and III–Vwere assayed similarly to core 2 β6-GlcNAc-
transferase, but using the acceptor substrates as indicated in the tables, and
12.5 mM MnCl2 in the assay. Enzyme products were separated by HPLC using
acetonitrile/water (16/84).Sialyltransferase assay mixtures contained 2 mM acceptor substrate, 0.1 M
Tris–HCl, pH 7.0, 0.125% Triton X-100, 5 mM MnCl2, and 1 mM CMP-[
3H]
sialic acid donor substrate (3000 cpm/nmol). The reaction mixtures from assays
of sialyltransferase acting on Galβ1-3GalNAcα-Bn substrate were filtered
through a 0.2 ml column of Bio-Gel P2, followed by HPLC separation using an
amine column. The mobile phase run at 1 ml/min was 81% acetonitrile/ 19%
15 mM potassium phosphate pH 5.2. After 60 min the concentration of
acetonitrile in the mobile phase was switched to 50% to elute CMP-sialic acid.
Rat colon mucosal homogenates were used as the positive control for all
transferase activities. Protein concentrations were determined with BIO-RAD
protein assay kits according to the manufacturer’s instructions, using bovine
serum albumin as the standard.
3. Results
Bovine chondrocytes from collagenase digested articular
cartilage of healthy cows grew well in primary cultures and
characteristically expressed collagen II. Western blots showed a
strong band for collagen II and a weak band for collagen I.
Chondrocytes isolated from knee cartilage of OA patients
typically grew very slow in culture [38].
The apoptotic effect of TNFα on BC was examined using
both Annexin V-biotin and TUNEL stains. The annexin Vassay
quantifies cells in early as well as late stages of apoptosis, while
the TUNEL stain quantifies DNA fragmentation. Fluorescence
microscopy using TUNEL staining identified a low number of
apoptotic BC in untreated controls (Fig. 2A), but a high number
of apoptotic BC after treatment with 40 ng/ml TNFα for 48 h
(Fig. 2B). Flow cytometry of a different preparation of TUNEL
Fig. 3. Cell proliferation of chondrocytes induced by TGFβ. Bovine
chondrocytes were grown in medium containing 5, 10 and 50 ng/ml TGFβ,
as indicated, for 48 h (A). Human chondrocytes (B) were grown in 10 ng/ml
TGFβ. Cell proliferation was measured with the [3H]Thymidine incorporation
assay and expressed as counts per minute (CPM).
Fig. 2. Fluorescence microscopy of TUNEL stained bovine chondrocytes after
treatment with TNFα. Bovine chondrocytes were treated with 40 ng/ml TNFα in
the cell medium for 48 h. Cells were stained with the Fluorescein FragELTM
(TUNEL) stain, and then examined by fluorescence microscopy. Control cells
(A) showed few stained cells, in contrast to cells treated with 40 ng/ml TNFα for
48 h (B) that showed a large number of apoptotic cells.
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apoptotic cell population after TNFα treatment. There was a
5.6-fold increase of cells in the early apoptotic stage and a 2-
fold increase in late apoptotic cells as shown by Annexin V
staining and flow cytometry. TNFα also caused a 10-fold
increase of cultured HC in the late apoptotic stage, seen after
Annexin V staining and flow cytometry.
While TNFα was found to induce apoptosis, TGFβ1 at a
concentration of 5 ng/ml significantly increased BC cell
numbers by 44% (p<0.05) in 48 h. Incubation of BC with 5,
10 and 50 ng/ml TGFβ for 48 h also significantly (p<0.05)
stimulated [3H]thymidine incorporation 2.3- to 3.3-fold in a
dose-dependent manner (Fig. 3A). Thus, TGFβ increased the
growth and proliferation of BC. TGFβ treatment also increased
the proliferation rate of HC by 37% (Fig. 3B).
Lectins were used in ELLA to determine the exposed
carbohydrate structures on the cell surfaces of chondrocytes.
The lectins wheat germ agglutinin (WGA), Sambucus nigra
(SNA), Peanut agglutinin (PNA), Maackia amurensis lectin
(MAA), Concanavalin A (ConA) and Helix pomatia (HP)were tested in two or three separate experiments with at least
eight measurements within each experiment. The binding
specificities of these lectins are indicated in Table 1. Since
all of these lectins bound to BC as well as to HC (Figs. 4,5),
it appeared that their ligand structures (e.g. GalNAc, O-
glycan core 1, sialic acids, N-glycans) were exposed on cell
surfaces.
BC treated with TNFα demonstrated significantly higher
binding to lectins WGA (55%), PNA (50%) and MAA (50%)
lectins (p<0.01) as well as SNA (35%) and ConA (23%)
(p<0.05), compared to untreated cells (Fig. 4A). These lectin
binding patterns suggested that significantly more GlcNAc or
sialic acid residues, Galβ1-3GalNAc- (O-glycan core 1), sialyl
α2-3 Gal and sialyl α2-6 Gal linkages, as well as N-glycan
core structures were exposed on cell surfaces after TNFα
treatment.
In contrast, TGFβ treatment of BC caused only a 5% but
significant decrease in the binding of WGA (p<0.05), and a 9%
decrease in MAA binding, as well as a 23% increase in the
binding of PNA lectin (p<0.01, Fig. 4B). Thus the exposure of
GlcNAc and sialyl α2–3 residues was reduced after TGFβ
treatment which is partly consistent with the greater exposure of
unmodified Gal β1-3GalNAc-structures.
HC were tested with SNA, PNA, MAA, ConA, and HP
lectins. The binding of SNA lectin significantly increased by
36% after TNFα treatment (Fig. 5A) while HP lectin binding
decreased by 17% (p<0.05). These patterns were distinct from
those obtained with BC although it appeared that in both cell
types significantly more sialylα2–6 Gal(NAc) linkages were
exposed after TNFα treatment. TGFβ treatment of HC at 5 ng/
ml and 48 h incubation time did not induce significant
Fig. 5. Lectin staining of human chondrocytes grown with and without TNFα
and TGFβ. Relative lectin binding intensities of HC are shown, quantified by
enzyme-linked lectin assay (ELLA), as described in Fig. 4. HC were treated with
(dark bars) or without (open bars) TNFα for 48 h (A), or with TGFβ for 48 h
(B). Cells were probed with lectins SNA, PNA, MAA, ConA, and HP, as
described in Fig. 4. Results represent the means and standard deviations of two
separate experiments (using cells from two different donors) with 8 wells per
treatment group (*p<0.05).
Fig. 4. Lectin staining of bovine chondrocytes grown with and without TNFα
and TGFβ. Relative lectin binding intensities of chondrocytes quantified by
enzyme-linked lectin assay (ELLA) are shown. Superconfluent BC were grown
with (dark bars) or without (light bars) TNFα for 48 h (A), or with TGFβ for
48 h (B). Cells were probed with lectins WGA (wheat germ agglutinin that binds
GlcNAc and sialic acid), SNA (Sambucus nigra lectin for sialylα2–6Gal(NAc)
termini), PNA (Peanut agglutinin for unmodified O-glycan core 1), MAA
(Maackia amurensis for sialyl α2–3 Gal linkages), ConA (Concanavalin A
lectin for Man residues of N-glycans) and HP (Helix pomatia lectin for
GalNAc). Results represent the means and standard deviations of three separate
experiments (using cells from 3 different cows) with 8 wells per treatment group
(*p<0.05; **p<0.01).
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was observed (Fig. 5B).
The alterations of carbohydrate epitopes upon cytokine
treatment suggested a shift in the biosynthesis of glycoproteins
in chondrocytes. Therefore, we determined the activities of
enzymes responsible for the synthesis of cell surface glycans
and secreted glycoproteins in chondrocyte homogenates.
Assays were performed for glycosyltransferase and sulfotrans-
ferase activities involved in the biosynthesis of glycoprotein-
bound N- and O-glycans (Table 2). Substrates were used at high
concentrations in the assays in order to compare the near-
maximal initial enzyme velocities. The first enzyme of the O-
glycosylation pathway, polypeptide GalNAc-transferase (Fig. 1,
path a), was assayed by HPLC using a synthetic peptide
substrate derived from the mucin MUC2 tandem repeat
sequence with one Thr as a potential O-glycosylation site,
Acetyl-BpaPTPPP-NH2 (Bpa=4-benzoyl-L-phenylalanine).
The activity was 2.6 nmol/h/mg in BC, and 27.7 nmol/h/mg
in HC cultures (Table 2). This confirms that both types of
chondrocytes actively synthesize O-glycans and the HP binding
sites (GalNAc-). However, HC had a 10.7-fold higher activity
of polypeptide GalNAc-transferase suggesting that O-glycosy-
lation in these cells is highly efficient. BC and HC also
synthesize core 1, the PNA binding site. Core 1 β3-Gal-
transferase activities which catalyze the second step of O-
glycosylation (Fig. 1, path b) were 1.5 nmol/h/mg in BC and
7.9 nmol/h/mg in HC cultures.The enzyme that synthesizes the branched O-glycan core 2
structure (Fig. 1, path c), core 2 β6-GlcNAc-transferase, was
not detectable in BC. This was confirmed in at least three
different primary cell cultures. In contrast, all HC cultures
exhibited a low but significant level of core 2 β6-GlcNAc-
transferase activity (Table 2). This suggests that the O-glycan
structures of human cells differ significantly from those of the
bovine cells. Thus HC can synthesize O-glycans with an
additional GlcNAcβ1–6 branch (core 2 structure) that can be
further modified to form complex structures.
Terminal GlcNAc residues of O-glycans can be extended by
β4- and β3-Gal-transferases. In order to determine which
activity is present in BC and HC, the enzyme products of Gal-
transferase assays, using GlcNAcα-Bn as a substrate, were
analyzed by HPLC in comparison with standard oligosacchar-
ides. The radioactive elution patterns showed that at least 95%
of the Gal-transferase activity was due to β4-Gal-transferase.
This activity was high in both BC (10.4 nmol/h/mg) and HC
(6.7 nmol/h/mg) (Fig. 1, path d).
Sulfotransferase activity towards the O-glycan core 1 substrate
(Fig. 1, path e) was not detected in either BC or HC, although the
activities were high in homogenates from rat colon. The α3-
sialyltransferase acting on the core 1 structure (Fig. 1, path f) was
assayed by HPLC and exhibited an activity of 0.4 nmol/h/mg in
BC.
The N-glycosylation pathways of glycoproteins were assessed
by measuring the GlcNAc-transferases that synthesize the
antennae of N-glycans in BC and HC. BC were shown to have
Table 4
TGFβ effects on glycosyltransferase activities in bovine and human
chondrocytes
Enzyme Substrate Activity
(% of
control)
BC HC
O-glycosylation pathway
Polypeptide
GalNAc-T
1 mM Acetyl-BpaPTPPP-NH2 71 154
Core 1 β3-Gal-T 2 mM GalNAcα-Bn 47 77
Core 2 β6-GlcNAc-T 2 mM Galβ3GalNAcα-Bn na 138
Core 1 α3-sialyl-T 2 mM Galβ3GalNAcα-Bn 100 nd
Core 1 3-O-sulfo-T 2 mM Galβ3GalNAcα-Bn na na
N-glycosylation pathway
GlcNAc-T I 1 mM Manα6(Manα3)Manβ-octyl 194 250
GlcNAc-T II 1 mM 6-deoxy-Manα6(GlcNAcβ2Manα3)
Manβ-octyl
208 117
GlcNAc-T III–V 1 mM GlcNAcβ2Manα6
(GlcNAcβ2Manα3)Manβ-octyl
na na
GlcNAc-T V 2 mM GlcNAcβ2Manα6Glcβ-pnp na nd
N- and O-glycosylation pathway
β4-Gal-T 2 mM GlcNAcβ-Bn 116 457
The activities are shown as percentages in treated cells compared to untreated
control cells.
Enzyme assays were carried out in at least duplicate determinations using
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GlcNAc-transferase II (2.6 nmol/h/mg). No activities of
GlcNAc-transferases III–V were detected (Table 2). This suggests
that BC synthesize complex bi-antennary N-glycans but not tri-
and tetra-antennary structures. HC also contained the activities of
GlcNAc-transferases I and II (but not III to V) and are therefore
also capable of synthesizing bi-antennary N-glycan structures.
To assess the effect of TNFα on the biosynthesis of
glycoproteins, the lectin binding changes of cells cultured for
24 h in the presence of 40 ng/ml TNFα were analyzed in
relation to the activities of glycosyltransferases (Table 3). In
BC, TNFα treatment resulted in a 3.2-fold increased activity of
polypeptide GalNAc-transferase. The activities of core 1 β3-
Gal-transferase and core 1 α3-sialyltransferase were un-
changed. This could explain the significant increase in PNA
binding sites of TNFα treated BC, since more GalNAc residues
may be present that can be converted to core 1.
In contrast to previous observations in bovine synoviocytes,
core 2 β6-GlcNAc-transferase activity was not increased by
TNFα in BC or HC [17]. GlcNAc-transferase I and II activities
exhibited minor differences between untreated and TNFα-
treated BC and HC. The greatest effect of TNFα on
glycosyltransferase activities was a 3.9-fold increase in β4-
Gal-transferase activity in BC. HPLC analyses showed that the
ratio of β4- to β3-Gal-transferase activities did not change afterTable 3
TNFα effects on glycosyltransferase activities in bovine and human
chondrocytes
Enzyme Substrate Activity
(% of
control)
BC HC
O-glycosylation pathway
Polypeptide
GalNAc-T
1 mM Acetyl-BpaPTPPP-NH2 319 101
Core 1 β3-Gal-T 2 mM GalNAcα-Bn 100 160
Core 2 β6-GlcNAc-T 2 mM Galβ3GalNAcα-Bn na 100
Core 1 α3-sialyl-T 2 mM Galβ3GalNAcα-Bn 100 nd
Core 1 3-O-sulfo-T 2 mM Galβ3GalNAcα-Bn na na
N-glycosylation pathway
GlcNAc-T I 1 mM Manα6(Manα3)Manβ-octyl 79 111
GlcNAc-T II 1 mM 6-deoxy-Manα6(GlcNAcβ2Manα3)
Manβ-octyl
150 110
GlcNAc-T III–V 1 mM GlcNAcβ2Manα6
(GlcNAcβ2Manα3)Manβ-octyl
na na
GlcNAc-T V 2 mM GlcNAcβ2Manα6Glcβ-pnp na nd
N- and O-glycosylation pathway
β4-Gal-T 2 mM GlcNAcβ-Bn 391 198
The activities are shown as percentages in treated cells compared to untreated
control cells.
Enzyme assays were carried out in at least duplicate determinations using
chondrocyte homogenates as described in Materials and methods. The values
obtained from duplicate determinations varied by <15%.HC samples were obtained
from OA patients that had undergone surgery for knee replacement. BC, bovine
chondrocytes; Bn, benzyl; Bpa, 4-benzoyl-L-phenylalanine; HC, human chondro-
cytes; na, no activity detected; nd, not determined; pnp, p-nitrophenyl; -T,
transferase.
chondrocyte homogenates as described in Materials and methods. The values
obtained from duplicate determinations varied by <15%. HC samples were
obtained from OA patients that had undergone surgery for knee replacement.
BC, bovine chondrocytes; Bn, benzyl; Bpa, 4-benzoyl-L-phenylalanine; HC,
human chondrocytes; na, no activity detected; nd, not determined; oct, octyl;
pnp, p-nitrophenyl; -T, transferase.cytokine treatment. Treatment of HC with TNFα was
accompanied by a 2-fold increase in β4-Gal-transferase and a
1.6-fold increase in core 1 β3-Gal-transferase activity. How-
ever, in contrast to BC, polypeptide GalNAc-transferase activity
was unchanged in HC (Table 3).
TGFβ treatment of BC caused a 29% decrease in activity of
polypeptide GalNAc-transferase and a 53% decrease in core 1
β3-Gal-transferase activity (Table 4). The core 1 α3-sialyl-
transferase activity was unchanged after TGFβ treatment. Thus,
it is possible that fewer core 1 structures were synthesized, but
according to the increased PNA binding, more of these core 1
structures remained unsubstituted. This is consistent with fewer
core 1 chains being α3-sialylated, as seen in a decrease in MAA
lectin binding after TGFβ treatment (Fig. 4B).
BC exhibited a 1.2-fold increase in β4-Gal-transferase
activity but 2-fold increases in both GlcNAc-transferase I and
II activities. Core 2 β6-GlcNAc-transferase activity was not
detectable in TGFβ-treated BC.
Although the lectin binding sites studied here were not
significantly altered in HC treated with TGFβ, a number of
transferase activities were found to be altered (Table 4). The
activity of polypeptide GalNAc-transferase was increased 1.5-
fold, of β4 Gal-transferase was increased 4.6-fold, and of
GlcNAc-transferase I was increased 2.5-fold after TGFβ
treatment of HC. This suggested that proliferating HC have a
270 X. Yang et al. / Biochimica et Biophysica Acta 1773 (2007) 264–272higher potential to synthesize both complex N- and O-glycans,
which precedes alterations in cell surface structures.
4. Discussion
In this study, we examined the glycodynamics of primary
bovine (BC) and human chondrocytes (HC) under inflamma-
tory conditions. The results showed a relationship between the
biosynthesis of glycoprotein-bound sugar chains and apoptosis
as well as cell proliferation. Chondrocytes have the ability to
produce many glycoproteins and proteoglycans with N-glycans
and mucin type O-glycans that function in the maintenance of
healthy cartilage. Our results show that BC and HC grown in
vitro have the enzymes that synthesize Asn-linked N-glycans
and Ser/Thr-linked O-glycans and expose specific carbohydrate
structures on their cell surfaces. BC and HC demonstrate many
similar characteristics and respond to TNFα by induction of
apoptosis and to TGFβ with cell proliferation. HC strikingly
differ from BC in their ability to synthesize complex core 2 type
O-glycans. HC were also found to differ in their responses to
TNFα and TGFβ. The differences between human and bovine
articular cartilage cells may be due to species differences.
Alternatively, tissues may differ in their glycosylation potential
and also in the response to cytokines. The different ages, as well
as the fact that human patients may have been afflicted with
arthritis are additional factors possibly determining the outcome
of this study. In future studies, these factors need to be
investigated independently.
In spite of the limited supply of cellular material from
chondrocyte primary cultures we were able to determine that
both HC and BC have a potential to synthesize bi-antennary N-
glycans. The presence of β4-Gal-transferase suggests that the
cells can further extend the terminal GlcNAc residues of the two
N-glycan antennae in the pathways to complex type chains. The
activities of GlcNAc-transferases III to V were below detectable
levels. Therefore, further branching to form tri- and tetra-
antennary structures is not likely to occur in BC and HC. This
coincides with N-glycan structures found in cartilage glyco-
proteins and proteoglycans [30,39–41]. These results also
correspond to reports by Richard et al. [33] who have assayed
glycosyltransferase activities in cartilage extracts from normal
and OA patients, utilizing glycoprotein substrates with multiple
but poorly defined glycosyl acceptor sites.
HC had an unusually high activity of the enzyme catalyzing
the first step of O-glycosylation, polypeptide GalNAc-transfer-
ase. The enzyme acted on a number of peptide substrates
containing one or more Thr residues which are excellent
substrates for polypeptide GalNAc-transferase T1 [11]. Both
BC and HC were able to synthesize core 1 based O-glycans, and
sialylα2-3Galβ1-3GalNAc structures. These O-glycan struc-
tures have been found in the bovine synovial mucin lubricin
[16]. In contrast to BC, HC could add a GlcNAc β1–6 branch to
form the core 2 structure (Fig. 1) catalyzed by core 2 β6-
GlcNAc-transferase [42]. Although core 2 β6-GlcNAc-trans-
ferase activity and core 2 structures have been found in a
number of bovine and human tissues and cell types [35,42,43],
the enzyme was not detected in any of the BC cultures, but in allof the HC cultures tested. Bovine chondrocyte and synovial
glycoproteins therefore appear to have only simple O-glycans
with core 1 structures [17,43]. TNFα treatment of HC reduced
HP binding and increased SNA binding. This suggests that
fewer GalNAc residues are exposed, and more core 1 structures
are synthesized due to the increased core 1 β3-Gal-transferase
activity. However, the unaltered PNA binding and increased
SNA binding could indicate that these core 1 structures are
converted to α6-sialylated core 1 structures. Future studies
should determine which sialyltransferase is altered in expres-
sion and activity after TNFα treatment. It is also possible that
other O-glycan extension reactions are altered [42].
An active β4Gal-transferase in HC extends core 2 structures.
Thus HC glycoproteins are expected to have complex branched
O-glycans which could carry antigenic epitopes (Fig. 1) [42],
keratan sulfate chains, as well as structures involved in cell
adhesion phenomena [39,44,45]. Large branched O-glycans
also have the ability to mask underlying structures [46,47]. We
have previously shown that TNFα treatment up regulated the
activity of core 2 β6-GlcNAc-transferase in bovine synovio-
cytes [17]; however, neither BC nor HC showed this up
regulation. The relatively low activity level of core 2 β6-
GlcNAc-transferase in HC is typical for many non-mucin
secreting cell types such as porcine endothelial cells [11]. From
the structures of bone and cartilage glycoproteins and
proteoglycans it can be derived that core 2 β6-GlcNAc-
transferase is also present in rat cartilage cells [40,41] and in
Swarm rat chondrosarcoma cells [48].
In the present study we found increased β4-Gal-transferase
activity in BC and HC upon both TNFα and TGFβ treatments.
This is consistent with results from Richard et al. [33] who
concluded that activities of several glycosyltransferases were
induced in cartilage tissues from OA patients. In those studies,
Gal-transferase activity towards orosomucoid substrate was
more than 10-fold increased while GlcNAc-transferase activ-
ities were similar between normal and OA cartilage. Based on
our findings, we predict that these changes may be a result of
increased levels of TNFα or other cytokines in OA cartilage.
Possible consequences of increased Gal-transferase activity
include the efficient extension of glycoprotein-bound N-glycans
as well as O-glycans with core 2 structures, thus forming the
basis for the attachment of terminal epitopes which can control
cell surface functions.
We determined here that two of the cytokines produced in
chondrocytes from OA cartilage, TNFα and TGFβ, affected cell
surface glycosylation but their effects were partly opposed to
each other. The effects of other cytokines, and combinations of
these, remain to be determined. Since cytokine receptors,
cytokines and other cell surface molecules involved in apoptosis
are glycoproteins, the changes in specific cell surface glycans
could potentially affect apoptosis and other signaling events
[49,50]. It is interesting that TNFα treatment increased the
activity of polypeptide GalNAc-transferase 3.2-fold in BC Tian
et al. [51] described an inhibitor of this enzyme that blocked
O-glycosylation and concomitantly induced apoptosis in
NIH3T3 cells. This indicates that especially O-glycosylation
is critically involved in apoptosis.
271X. Yang et al. / Biochimica et Biophysica Acta 1773 (2007) 264–272The effects of the pro-apoptotic cytokine TNFα and the
proliferation-inducing cytokine TGFβ included cytokine-
specific and possibly cell-specific effects on the biosynthesis
of glycoproteins. The control of biosynthesis in vivo, however,
is very complex and involves many more enzymes and factors,
including the intracellular organization of glycosylation. The
site of glycoprotein biosynthesis, the Golgi apparatus, has
been reported to be abnormal in structure in a rat model of OA
[52]. Such alteration may be due to the effects of cytokines
and can affect the delicate balance of enzyme activities
involved in the assembly of complex glycan chains in arthritis.
It remains to be established if the effects of cytokines on cell
surface glycans synthesized in vivo, and on the enzyme
activities measured in vitro, are mediated through the initiation
of the apoptotic pathway or are a growth-related phenomenon,
or are due to a more direct effect of cytokine signaling [8,53].
The long-term effects of cytokine stimulation on cartilage
cells, and the consequences of a combination of cytokines
remain to be determined. In addition, the human chondrocytes
were derived from patients with osteoarthritis, and this
condition may be related to the generally poor cell growth
and poor responses to cytokines. It also remains to be
established if the effects observed here are a function of the
patient’s age. The present results showed that glycans are in a
dynamic equilibrium in cartilage cells, and form the basis for
further investigations of the mechanisms underlying inflam-
mation in arthritis.
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